An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects With Relapsed/Refractory Multiple Myeloma (KarMMa-7)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Idecabtagene vicleucel (Primary) ; Bortezomib; Crenigacestat; Dexamethasone; Iberdomide; Pomalidomide
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Acronyms KarMMa-7
Sponsors Celgene Corporation

Most Recent Events

06 Jul 2023 Status changed from recruiting to active, no longer recruiting.
17 Aug 2022 Planned End Date changed from 20 Apr 2026 to 6 Dec 2026.
17 Aug 2022 Planned primary completion date changed from 24 Nov 2024 to 23 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight